Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In vitro biomimetic models have become increasingly utilised in the evaluation of medical devices over the last 30 years.
Application in the field of Interventional Oncology for modelling purposes has been limited by the complexity of recreating
biological vascular systems. Interventional Oncology and specifically embolisation, varies significantly in terms of its
administration methodology. The specific process of blocking the primary blood supply to a hyper-vascularised tumour is
anything but simple in terms of reproducibility and translation between patients, clinics and devices. Flow properties of drugloaded
embolic microspheres have been shown to influence the distribution, contact diffusion and spatial drug elution kinetics
within tumours. Moreover, variations in the administration style of the physician have been shown to play a significant part in
the intra-tumoural distribution. To model the unique flow properties of various embolic products, novel in vitro microfluidic
test systems have been developed. Through compartmentalised recreations of clinical conditions, it becomes possible to
predict and evaluate relevant flow properties prior to use in vivo. This presentation will analyse the effect of channel flow rate
(Reynold’s number) and embolic size of doxorubicin loaded DC Bead™ 70-150μm and 100-300μm within in vitro flow channels
of sizes representative of distal hepatic microvasculature. The effect of whole bead distribution is considered as a vehicle for
distal drug distribution utilising clinically representative injection volumes for modelling bolus effects. A significantly higher
dose (p=0.017) is observed in smaller flow channels with 70-150μm vs 100-300μm trending with increased flow rates.
Marcus is an Innovation Scientist at BTG. Initially focusing on analytical method development and validation, he is currently completing a part-time PhD with the University of Southampton in Applied Biomimetic Microfluidics and focusing on the application of this project to advancing treatment in the field of interventional oncology and pulmonology.